Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: Identification of functional disparities between azacytidine and decitabine

Yao Yu Hsieh, Tsui Chin Huang, Hsiang Ling Lo, Jyun Yan Jhan, Shui Tein Chen, Pei Ming Yang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Polypharmacology (the ability of a drug to affect more than one molecular target) is considered a basic property of many therapeutic small molecules. Herein, we used a chemical genomics approach to systematically analyze polypharmacology by integrating several analytical tools, including the LINCS (Library of Integrated Cellular Signatures), STITCH (Search Tool for Interactions of Chemicals), and WebGestalt (WEB-based GEne SeT AnaLysis Toolkit). We applied this approach to identify functional disparities between two cytidine nucleoside analogs: azacytidine (AZA) and decitabine (DAC). AZA and DAC are structurally and mechanistically similar DNA-hypomethylating agents. However, their metabolism and destinations in cells are distinct. Due to their differential incorporation into RNA or DNA, functional disparities between AZA and DAC are expected. Indeed, different cytotoxicities of AZA and DAC toward human colorectal cancer cell lines were observed, in which cells were more sensitive to AZA. Based on a polypharmacological analysis, we found that AZA transiently blocked protein synthesis and induced an acute apoptotic response that was antagonized by concurrently induced cytoprotective autophagy. In contrast, DAC caused cell cycle arrest at the G2/M phase associated with p53 induction. Therefore, our study discriminated functional disparities between AZA and DAC, and also demonstrated the value of this chemical genomics approach that can be applied to discover novel drug action mechanisms.

Original languageEnglish
Pages (from-to)27363-27378
Number of pages16
JournalOncotarget
Volume7
Issue number19
DOIs
Publication statusPublished - May 10 2016

Fingerprint

decitabine
Azacitidine
Drug Discovery
Genomics
Polypharmacology
Cytidine
G2 Phase
DNA
Autophagy
Cell Cycle Checkpoints
Nucleosides
Pharmaceutical Preparations
Cell Division
Libraries
Colorectal Neoplasms

Keywords

  • Colorectal cancer
  • DNMT inhibitor
  • Drug repurposing
  • Polypharmacology
  • Systems pharmacology

ASJC Scopus subject areas

  • Oncology

Cite this

Systematic discovery of drug action mechanisms by an integrated chemical genomics approach : Identification of functional disparities between azacytidine and decitabine. / Hsieh, Yao Yu; Huang, Tsui Chin; Lo, Hsiang Ling; Jhan, Jyun Yan; Chen, Shui Tein; Yang, Pei Ming.

In: Oncotarget, Vol. 7, No. 19, 10.05.2016, p. 27363-27378.

Research output: Contribution to journalArticle

@article{db2819bb481b4dd18f6f265ae07b722d,
title = "Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: Identification of functional disparities between azacytidine and decitabine",
abstract = "Polypharmacology (the ability of a drug to affect more than one molecular target) is considered a basic property of many therapeutic small molecules. Herein, we used a chemical genomics approach to systematically analyze polypharmacology by integrating several analytical tools, including the LINCS (Library of Integrated Cellular Signatures), STITCH (Search Tool for Interactions of Chemicals), and WebGestalt (WEB-based GEne SeT AnaLysis Toolkit). We applied this approach to identify functional disparities between two cytidine nucleoside analogs: azacytidine (AZA) and decitabine (DAC). AZA and DAC are structurally and mechanistically similar DNA-hypomethylating agents. However, their metabolism and destinations in cells are distinct. Due to their differential incorporation into RNA or DNA, functional disparities between AZA and DAC are expected. Indeed, different cytotoxicities of AZA and DAC toward human colorectal cancer cell lines were observed, in which cells were more sensitive to AZA. Based on a polypharmacological analysis, we found that AZA transiently blocked protein synthesis and induced an acute apoptotic response that was antagonized by concurrently induced cytoprotective autophagy. In contrast, DAC caused cell cycle arrest at the G2/M phase associated with p53 induction. Therefore, our study discriminated functional disparities between AZA and DAC, and also demonstrated the value of this chemical genomics approach that can be applied to discover novel drug action mechanisms.",
keywords = "Colorectal cancer, DNMT inhibitor, Drug repurposing, Polypharmacology, Systems pharmacology",
author = "Hsieh, {Yao Yu} and Huang, {Tsui Chin} and Lo, {Hsiang Ling} and Jhan, {Jyun Yan} and Chen, {Shui Tein} and Yang, {Pei Ming}",
year = "2016",
month = "5",
day = "10",
doi = "10.18632/oncotarget.8455",
language = "English",
volume = "7",
pages = "27363--27378",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "19",

}

TY - JOUR

T1 - Systematic discovery of drug action mechanisms by an integrated chemical genomics approach

T2 - Identification of functional disparities between azacytidine and decitabine

AU - Hsieh, Yao Yu

AU - Huang, Tsui Chin

AU - Lo, Hsiang Ling

AU - Jhan, Jyun Yan

AU - Chen, Shui Tein

AU - Yang, Pei Ming

PY - 2016/5/10

Y1 - 2016/5/10

N2 - Polypharmacology (the ability of a drug to affect more than one molecular target) is considered a basic property of many therapeutic small molecules. Herein, we used a chemical genomics approach to systematically analyze polypharmacology by integrating several analytical tools, including the LINCS (Library of Integrated Cellular Signatures), STITCH (Search Tool for Interactions of Chemicals), and WebGestalt (WEB-based GEne SeT AnaLysis Toolkit). We applied this approach to identify functional disparities between two cytidine nucleoside analogs: azacytidine (AZA) and decitabine (DAC). AZA and DAC are structurally and mechanistically similar DNA-hypomethylating agents. However, their metabolism and destinations in cells are distinct. Due to their differential incorporation into RNA or DNA, functional disparities between AZA and DAC are expected. Indeed, different cytotoxicities of AZA and DAC toward human colorectal cancer cell lines were observed, in which cells were more sensitive to AZA. Based on a polypharmacological analysis, we found that AZA transiently blocked protein synthesis and induced an acute apoptotic response that was antagonized by concurrently induced cytoprotective autophagy. In contrast, DAC caused cell cycle arrest at the G2/M phase associated with p53 induction. Therefore, our study discriminated functional disparities between AZA and DAC, and also demonstrated the value of this chemical genomics approach that can be applied to discover novel drug action mechanisms.

AB - Polypharmacology (the ability of a drug to affect more than one molecular target) is considered a basic property of many therapeutic small molecules. Herein, we used a chemical genomics approach to systematically analyze polypharmacology by integrating several analytical tools, including the LINCS (Library of Integrated Cellular Signatures), STITCH (Search Tool for Interactions of Chemicals), and WebGestalt (WEB-based GEne SeT AnaLysis Toolkit). We applied this approach to identify functional disparities between two cytidine nucleoside analogs: azacytidine (AZA) and decitabine (DAC). AZA and DAC are structurally and mechanistically similar DNA-hypomethylating agents. However, their metabolism and destinations in cells are distinct. Due to their differential incorporation into RNA or DNA, functional disparities between AZA and DAC are expected. Indeed, different cytotoxicities of AZA and DAC toward human colorectal cancer cell lines were observed, in which cells were more sensitive to AZA. Based on a polypharmacological analysis, we found that AZA transiently blocked protein synthesis and induced an acute apoptotic response that was antagonized by concurrently induced cytoprotective autophagy. In contrast, DAC caused cell cycle arrest at the G2/M phase associated with p53 induction. Therefore, our study discriminated functional disparities between AZA and DAC, and also demonstrated the value of this chemical genomics approach that can be applied to discover novel drug action mechanisms.

KW - Colorectal cancer

KW - DNMT inhibitor

KW - Drug repurposing

KW - Polypharmacology

KW - Systems pharmacology

UR - http://www.scopus.com/inward/record.url?scp=84968719159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84968719159&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8455

DO - 10.18632/oncotarget.8455

M3 - Article

C2 - 27036028

AN - SCOPUS:84968719159

VL - 7

SP - 27363

EP - 27378

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 19

ER -